A groundbreaking clinical trial shows that giving immunotherapy before surgery may transform outcomes for colorectal cancer patients. In the NEOPRISM-CRC study, treatment with pembrolizumab for just nine weeks led to remarkable results — no patient experienced cancer recurrence after nearly three years.
Around 59% of patients had no detectable cancer even before surgery, and others remained stable without progression.
Researchers also developed personalized blood tests to track tumor DNA, helping predict treatment success.
This approach could replace chemotherapy for some patients, offering more effective, personalized, and long-lasting cancer care.
Read more at ScienceDaily
